Format

Send to

Choose Destination
See comment in PubMed Commons below
J Clin Immunol. 2007 Jul;27(4):363-71. Epub 2007 Mar 17.

Toll or toll-free adjuvant path toward the optimal vaccine development.

Author information

1
Exploratory Research for Advanced Technology (ERATO), Japan Science and Technology Agency (JST), Osaka University, Suita, Osaka 565-0871, Japan. kenishii@biken.osaka-u.ac.jp

Abstract

Successful vaccines contain an adjuvant component that activates the innate immune system, thereby eliciting antigen-specific immune responses. Many adjuvants appear to be ligands for toll-like receptors (TLR), which are thus promising targets for the development of novel adjuvants to elicit vaccine immunogenicity. However, recent evidence suggests that some adjuvants activate the innate immune system in a TLR-independent manner possibly through other pattern recognition receptors and signaling machinery. In particular, newly identified intracellular retinoic-acid-inducible gene (RIG)-like receptors, NOD-like receptors, or even as yet unknown recognition machinery for the adjuvant may regulate TLR-independent vaccine immunogenicity. To develop optimal vaccines, it will be critical to understand how TLR-dependent and TLR-independent innate immune activation, by various adjuvants, control the consequent adaptive immune responses to vaccine.

PMID:
17370119
DOI:
10.1007/s10875-007-9087-x
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Springer
    Loading ...
    Support Center